Progress of ibrutinib combined with CD19 chimeric antigen receptor T-cell in treatment of chronic lymphocytic leukemia

VernacularTitle:伊布替尼联合CD19嵌合抗原受体T细胞治疗慢性淋巴细胞白血病的研究进展
Author: Jun JIAO ¹ ; Qinqin LIU ; Qingliang TENG ; Ling WANG
Author Information

1. 山东省泰安市中心医院血液科，泰安　271000
Keywords: Leukemia, lymphocytes, chronic; Ibrutinib; CD19; Chimeric antigen receptor T-cell
From: Journal of Leukemia & Lymphoma 2023;32(7):445-448
CountryChina
Language:Chinese
Abstract: Chronic lymphocytic leukemia (CLL) is a clonal malignant disease of B lymphocytes (T lymphocytes are rare) and usually occurs in elderly people. CLL has a highly variable clinical course, with a median survival of 35 to 63 months. In the era of immunochemotherapy, the survival of CLL patients has improved significantly, but most patients still have primary drug resistance and relapse after the treatment. The emergence of Bruton tyrosine kinase inhibitor has completely changed the treatment mode of CLL, making the treatment of CLL into the era of targeted therapy. Ibrutinib combined with CD19 chimeric antigen receptor T-cell has good efficacy and can improve the prognosis of patients.